Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low

Reviews 139

Timing of kidney replacement therapy initiation for acute kidney injury

Fayad, AI, Buamscha, DG, et al. · Cochrane Database of Systematic Reviews · 2022

Kidney and Transplant

Thinnest evidence

Reviews 139

Timing of kidney replacement therapy initiation for acute kidney injury

Interventions for improving health literacy in people with chronic kidney disease

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients

Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access

Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis

D‐mannose for preventing and treating urinary tract infections

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease

Exercise training for adults undergoing maintenance dialysis

Synbiotics, prebiotics and probiotics for solid organ transplant recipients

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome

Altered dietary salt intake for people with chronic kidney disease

Interventions for increasing solid organ donor registration

Interventions for preventing thrombosis in solid organ transplant recipients

Exercise training for adult lung transplant recipients

Interventions for atypical haemolytic uraemic syndrome

Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome

Aldosterone antagonists for people with chronic kidney disease requiring dialysis

Interventions for weight loss in people with chronic kidney disease who are overweight or obese

Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy

Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D

Corticosteroid therapy for nephrotic syndrome in children

Low protein diets for non‐diabetic adults with chronic kidney disease

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children

Interventions for renal vasculitis in adults